Health News

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

Read more

Filed under: Pharmacy News
Tags: cancer, Drug, gene, Pharmacy

Related posts

• Vorinostat in addition to chemotherapy drugs improves remission rates in AML patients (0)
  Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology. Read more [tags] Pharmacy News [/tags]
  
  
• Targeting mutant BRAF can kill cancer cells, but cannot finish off melanoma (0)
  This past summer saw a revolution in melanoma therapy. Patients whose melanoma lesions contain a mutation in the BRAF gene were successfully treated with a BRAF-specific inhibitor, PLX4032. Reports of the drug trial described shrinking tumors and improved health. Yet seven months after therapy began the tumors returned and resumed growing. Now, scientists at The [...]
  
  
• Study: AEG-1 expression predicts erlotinib treatment response in patients with EGFR-mutant lung cancer (0)
  Spanish researchers have identified a gene whose expression level strongly predicts how well certain lung cancer patients will respond to treatment with the drug erlotinib. Read more [tags] Pharmacy News [/tags]
  
  
• Study finds Olaparib can reduce tumor size in ovarian cancer women (0)
  Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations. Read [...]
  
  
• Response to PLX4032 drug short lived in BRAF-mutated metastatic melanoma patients (0)
  Researchers with UCLA's Jonsson Comprehensive Cancer Center have found that melanoma patients whose cancers are caused by mutation of the BRAF gene become resistant to a promising targeted treatment through another genetic mutation or the overexpression of a cell surface protein, both driving survival of the cancer and accounting for relapse. Read more [tags] Pharmacy News [/tags]